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OATP1B1-related drug–drug and drug–gene interactions as
potential risk factors for cerivastatin-induced rhabdomyolysis
Bani Tamraza, Hisayo Fukushimad,e, Alan R. Wolfed,e, Ru¨diger Kasperaj,
Rheem A. Totahj, James S. Floydf,g, Benjamin Maa, Catherine Chua,
Kristin D. Marciantef,g, Susan R. Heckbertf,h,k, Bruce M. Psatyf,g,h,i,k,
Deanna L. Kroetzc,d and Pui-Yan Kwoka,b,c
Objective Genetic variation in drug metabolizing enzymes
and membrane transporters as well as concomitant drug
therapy can modulate the beneficial and the deleterious
effects of drugs. We investigated whether patients
exhibiting rhabdomyolysis who were taking cerivastatin
possess functional genetic variants in SLCO1B1 and
whether they were on concomitant medications that inhibit
OATP1B1, resulting in accumulation of cerivastatin.
Methods This study had three components:
(a) resequencing the SLCO1B1 gene in 122 patients
who developed rhabdomyolysis while on cerivastatin;
(b) functional evaluation of the identified SLCO1B1
nonsynonymous variants and haplotypes in in-vitro
HEK293/FRT cells stably transfected with pcDNA5/FRT
empty vector, SLCO1B1 reference, variants, and
haplotypes; and (c) in-vitro screening of 15 drugs
commonly used among the rhabdomyolysis cases for
inhibition of OATP1B1-mediated uptake of cerivastatin
in HEK293/FRT cells stably transfected with reference
SLCO1B1.
Results The resequencing of the SLCO1B1 gene identified
54 variants. In-vitro functional analysis of SLCO1B1
nonsynonymous variants and haplotypes showed that
the V174A, R57Q, and P155T variants, a novel frameshift
insertion, OATP1B1*14 and OATP1B1*15 haplotype were
associated with a significant reduction (P<0.001) in
cerivastatin uptake (32, 18, 72, 3.4, 2.1 and 5.7% of
reference, respectively). Furthermore, clopidogrel
and seven other drugs were shown to inhibit
OATP1B1-mediated uptake of cerivastatin.
Conclusion Reduced function of OATP1B1 related to
genetic variation and drug–drug interactions likely
contributed to cerivastatin-induced rhabdomyolysis.
Although cerivastatin is no longer in clinical use, these
findings may translate to related statins and other
substrates of OATP1B1. Pharmacogenetics and Genomics
23:355–364 c 2013 Wolters Kluwer Health | Lippincott
Williams & Wilkins.
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Introduction
Statins, inhibitors of 3-hydroxy-3-methylglutaryl coenzyme-
A reductase, are the most potent cholesterol lowering
agents. Generally, statins are well tolerated and have
acceptable safety profiles. Adverse drug reactions associated
with statins include asymptomatic elevation of hepatic
transaminases, extremely rare cases of hepatitis, and skeletal
muscle-related complaints that in very rare cases can
progress to rhabdomyolysis, the most serious side effect of
these drugs. Cerivastatin (Baycol), a potent synthetic
inhibitor of 3-hydroxy-3-methylglutaryl coenzyme-A reduc-
tase, was removed from the US market in August 2001, only
3 years after approval, because of its high reported incidence
of rhabdomyolysis compared with existing statins [1].
Although the mechanism of rhabdomyolysis associated
with statins is not yet elucidated, data support an
increase in the relative risk of rhabdomyolysis when
statins are administered concomitantly with drugs that
inhibit their metabolism [2–4] or in the presence of the
521T>C variant of SLCO1B1 that reduces transporter
function [5,6].
The epidemiologic arm of a recent case–control analysis
published by our group identified the use of seven
medications (gemfibrozil, fluoxymesterone, clopidogrel,
rosiglitazone, rofecoxib, lansoprazole, and propoxyphene)
to be significantly associated with an increased risk of
cerivastatin-induced rhabdomyolysis. Furthermore, these
data identified clopidogrel use to be strongly associated
with cerivastatin-induced rhabdomyolysis both in the
presence [odds ratio (OR) 29.6; 95% confidence interval
(CI), 6.1–143] and absence (OR 47.8; 95% CI, 12.5–182) of
gemfibrozil use [7]. The clopidogrel finding was further
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replicated using US Food and Drug Administration Adverse
Event Reporting System data (OR N; 95% CI, 2.6–N)
and supported by in-vitro data demonstrating inhibition of
CYP2C8-mediated and CYP3A4-mediated metabolism of
cerivastatin by clopidogrel or its metabolites [7].
An association analysis of single nucleotide polymorph-
isms identified by sequencing SLCO1B1, CYP2C8,
UGT1A1, and UGT1A3 in the same cerivastatin-induced
rhabdomyolysis cases identified the SLCO1B1 521T>C
polymorphism as associated with the risk of rhabdomyo-
lysis (OR 1.89; 95% CI 1.40–2.56) [6]. Furthermore, in-
vitro cellular uptake data showed a 40% reduction in
cerivastatin uptake with this polymorphism [6]. This
particular polymorphism was identified in a genome-wide
association study of myopathy in patients with a history of
myocardial infarction who used simvastatin at a daily dose
of 80mg [5].
Here, we report the functional consequences of addi-
tional nonsynonymous SLCO1B1 gene variants identified
in 122 individuals who developed rhabdomyolysis while
taking cerivastatin. In addition, we conducted an in-vitro
drug–drug interaction screen of 15 medications identified
in the epidemiologic study to identify potential inhibitors
of OATP1B1-mediated cerivastatin uptake.
Methods
Compounds
[3H]-Cerivastatin sodium salt (CER) (1mCi/ml; specific
activity 5Ci/mmol) was purchased from American Radio-
labeled Chemicals (St Louis, Missouri, USA) and was
purified by high-performance liquid chromatography to
remove degradation products. [3H]-Estrone-3-sulfate
ammonium salt (ES) (1mCi/ml; specific activity 50Ci/
mmol) was purchased from PerkinElmer Inc. (Boston,
Massachusetts, USA). Clopidogrel hydrogen sulfate,
rifampin, and celecoxib were purchased from Sigma-
Aldrich (St Louis, Missouri, USA). Irbesartan, rofecoxib,
pioglitazone hydrochloride, montelukast sodium, verapa-
mil, diltiazem, glyburide, amlodipine, clopidogrel thio-
lactone, and lansoprazole were purchased from Santa
Cruz Biotechnology Inc. (Santa Cruz, California, USA).
Rosiglitazone-potassium salt was purchased from Cayman
Chemical (Ann Arbor, Michigan, USA).
DNA samples, PCR, and sequencing
DNA from 126 individuals confirmed to have rhabdo-
myolysis while on cerivastatin was used for sequencing
the SLCO1B1 gene. A detailed description of the cases
and the recruitment process is found in our previous
reports [6–8]. A detailed description of PCR and
sequencing of our samples method is also previously
reported [6]. Data from four individuals of Asian, mixed,
or unknown ethnicity were excluded from the current
analysis.
Construction of SLCO1B1 reference and variant
plasmids
The SLCO1B1 reference cDNA, containing exons 2–15
and three bases in the 30-untranslated region, was cloned
from human liver tissue and inserted into the pCR2.1-
TOPO vector (Invitrogen, Carlsbad, California, USA) and
subsequently inserted into pcDNA5/FRT vector (Invi-
trogen). Plasmids containing the variants and haplotypes
were constructed by site-directed mutagenesis (SDM)
using a QuickChange Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, California, USA) according to the
manufacturer’s protocol. The primer sequences (primer
sequences available upon request) for the SDM were
designed using QuickChange Primer Design Program
(http://www.stratagene.com/sdmdesigner/default.aspx) from Stra-
tagene. PCR for the SDM was performed under the
following conditions: 30 s at 951C for denaturation/
activation followed by 15 cycles of 951C for 30 s, 1min
at 551C, and 681C for 14.5min.
The SDM product was digested with Dpn I and incubated
for 1 h at 371C to remove the methylated reference plasmid.
The Dpn I digested product was transformed into XL1-blue
supercompetent cells (Stratagene). Plasmids were purified
with QIAfilter Plasmid Midi Kits (Qiagen Inc., Valencia,
California, USA) and sequenced using ABI PRISM BigDye
terminator sequencing version 3.1 on an ABI Prism 3730xl
DNA analyzer (Applied Biosystems, Foster City, California,
USA) to verify the insertion of the variant.
Construction of stable human SLCO1B1 expressing
cell lines
Human embryonic kidney epithelial Flp-In (HEK293/
FRT) cells (Invitrogen) were stably transfected with
pcDNA5/FRT (empty vector), pcDNA5/FRT/SLCO1B1
reference, and pcDNA5/FRT/SLCO1B1 variant plasmids
using FuGENE 6 transfection reagent (Roche Applied
Sciences, Mannheim, Germany). Briefly, on the day
before transfection, 1.5 105 HEK293/FRT cells were
seeded in a 24-well plate (BD Biosciences Discover
Labware, Bedford, Massachusetts, USA) and incubated
for 24 h in Dulbecco’s modified Eagle’s medium 4.5%
glucose (DMEM-H-21; UCSF Cell Culture Facility, San
Francisco, California, USA) and 10% heat inactivated fetal
bovine serum (UCSF Cell Culture Facility). The next day
cells were transfected with a DNA:FuGENE 6 complex
containing the SLCO1B1 plasmids, pOG44, a Flp-
recombinase expression vector (Invitrogen), FuGENE 6,
and Opti-MEM (UCSF Cell Culture Facility). The cells
were incubated at 371C, greater than 95% relative
humidity, and 5% CO2, and selection media containing
150 mg/ml of hygromycin B (Invitrogen), 100 mg/ml zeocin
(Invitrogen), 1% penicillin and streptomycin (UCSF Cell
Culture Facility), and 89% DMEM-H-21 was added 48 h
after transfection. Colonies were isolated and screened
for the expression of SLCO1B1 using reverse-transcrip-
tion quantitative PCR (RT-qPCR).
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RT-qPCR expression assay
Total RNA was isolated from each individual cell colony
using RNeasy Plus Micro Kit (Qiagen) per manufac-
turer’s protocol. The isolated RNA was used to make
cDNA via iScript cDNA Synthesis kit (Bio-Rad Labora-
tories, Hercules, California, USA) per manufacturer’s
protocol followed by quantitative PCR (qPCR). A
singleplex qPCR reaction mix for SLCO1B1 gene
included cDNA, the forward (50-TCTTCTCTTGTTGG
TTTTATTGACG-30), and reverse (30-TCCCATAATGAA
ACAACCGATTC-50) primers both at 1 mmol/l and Power
SYBR Green PCR Master Mix (Applied Biosystems).
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was the internal control gene in a separate singleplex
qPCR reaction for the same cDNA. Real-time qPCR for
each variant was repeated four times. The qPCR reaction
was analyzed using an Applied Biosystems Prism7900HT
Real-Time PCR System with cycling conditions of
denaturation at 951C for 10min followed by 40 cycles
of 951C for 15 s and 601C for 1min. The qPCR data was
analyzed by 7900HT version 2.3 Sequence Detection
Systems software (Applied Biosystems).
The PCR efficiency (E) was measured using standard
curves generated by serial dilutions of RNA and
calculated by the formula:
E¼101=slope1:
To analyze the data from RT-qPCR experiments the
2DDCt method was used to assess the relative changes in
gene expression. Details of this method have been
previously described [9].
Functional cellular assays
Stably transfected HEK293/FRT cells expressing the
empty vector, SLCO1B1 reference, variants, and haplo-
types were plated onto poly-D-lysine-coated 24-well
plates (BD Biosciences Discover Labware). Cerivastatin
cellular accumulation studies were performed 24 h after
cell seeding. The accumulation study started with
incubation with either 5 nmol/l [3H]-CER or 20 nmol/l
[3H]-ES for 5min at 371C. Concentrations of substrate
and reaction times were selected to be in the linear range
of transport. The cerivastatin concentration is also
clinically relevant [10,11].
Accumulation was stopped by removing the media and
washing the cells three times with ice-cold Krebs–
Henseleit buffer. The cells were lysed by addition of
0.1N NaOH and 0.1% sodium dodecyl sulfate. The
intracellular concentration of cerivastatin was measured
by liquid scintillation counting. The disintegration per
minute value for each sample, measured on a LS-6500
Multi-Purpose Scintillation Counter (Beckman Coulter,
Brea, California, USA), was normalized to the sample
protein concentration measured using a BCA protein
assay kit (Pierce Biotechnology Inc., Rockford, Illinois,
USA). The OATP1B1-mediated uptake for each variant
was determined by subtracting the rate of uptake in
empty vector cells from the uptake in cells expressing
OATP1B1 reference or variant transporters. Specific
transport rates were then expressed relative to reference
values. Transport assays were performed in quadruplicate
and repeated a minimum of two times.
Analysis of potential drug–drug interactions used condi-
tions identical to those of the accumulation assays
described above, with the exception that 100, 50, 10, 1
and 0.1 mmol/l concentrations of various compounds were
included in the reactions. All uptake values are corrected
for background and expressed relative to no inhibitor.
IC50 values were extrapolated from curves fitted to the
experimental data by GraphPad Prism software, version
5.04 (GraphPad Software Inc., San Diego, California,
USA).
Statistical analysis
Significant differences in ES or cerivastatin uptake
between reference and variant OATP1B1 transporters
and in the presence and absence of potential inhibitors
were detected by one-way analysis of variance followed
by Bonferroni’s correction for multiple testing and post-
hoc multiple comparison testing. Haplotypes for non-
synonymous SLCO1B1 genotype data of rhabdomyolysis
cases were inferred using PHASE and fastPHASE
(University of Washington, Washington, USA) software
programs [12].
Prediction of clinical drug–drug interactions
To predict whether an in-vitro finding of reduced uptake
is clinically significant, the decision tree for OATP
interactions proposed in the International Transporter
Consortium (ITC) paper by Giacomini et al. [13] was
followed. The fraction unbound, fu, and maximum plasma
concentration, Cmax, values for each compound were
obtained from the literature. If
unboundCmax
IC50
 0:1; where unboundCmax¼fuCmax;
then we calculated the R value, representing the ratio of
the uptake clearance in the absence and presence of the
inhibitor:
R¼1þ fuIin;max
IC50
;
where fu is the protein unbound fraction of the inhibitor
and Iin, max is the estimated maximum inhibitor blood
concentration at the inlet to the liver and is calculated
using the following equation:
Iin;max¼Cmaxþ Fadose Ka
Qh
 
;
where Fa is the fraction of the dose of the inhibitor, dose,
that is absorbed from the intestine, Ka is the absorption
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rate constant of the inhibitor at the intestine, and Qh is
the hepatic blood flow (1500ml/min). Fa was set to 1 and
Ka was set at 0.1 /min [14]. For R values greater than 2
(ITC recommendation [13]) or greater than or equal to
1.25 (Food and Drug Administration – Center for Drug
Evaluation and Research recommendation [15]), the
in-vitro interaction finding may be clinically significant
and a clinical study is recommended [13].
Results
SLCO1B1 sequencing in cerivastatin rhabdomyolysis
cases
In sequencing the SLCO1B1 gene we identified a total of
54 variants, which we have previously listed in supple-
mentary material of Marciante et al. [6] publication. Of
these, 10 were found in exons, whereas 44 were outside of
the exons. Of the coding variants, seven were nonsynon-
ymous (Table 1). rs113495867 resulted in insertion of GT
in exon 9 that caused a frameshift (FS) in the latter half
of the SLCO1B1 gene and introduction of a stop codon at
amino acid 344 leading to premature termination and a
transporter that is 347 amino acids shorter than the
reference. The variants rs61760183, rs61760243, and
rs113495867 were singletons, found as heterozygous
changes in three different individuals.
A haplotype analysis of all the SLCO1B1 nonsynonymous
coding variants revealed common (frequency>1%)
known and novel haplotypes. Table 2 lists the common
haplotypes, the nonsynonymous nucleotides, and their
corresponding frequencies on the basis of the two ethnic
groups in our cases.
ES uptake transport by SLCO1B1 variants and
haplotypes
Ten SLCO1B1 stable HEK293/FRT cell lines were
created for this study. They expressed six variants, two
haplotypes, the reference sequence, and empty vector.
Numerous attempts to create stable cells lines expressing
1929A>C variant and its corresponding haplotype, *35
were not successful. The level of SLCO1B1 mRNA
expression was analyzed by RT-qPCR and found to be
similar among the reference and variant cell lines (Fig. 1).
Uptake of ES, a prototypical substrate of OATP1B1, by
reference and variant transporters is shown in Fig. 2.
Transport of ES by cells containing the OATP1B1
Table 1 SLCO1B1 coding SNPs identified in rhabdomyolysis cases
Minor allele frequencies
All cases HAPMAPb 1000 genome Pasanen et al. [16]c
SNP ID Location
Location in gene/
protein
Black
(n=4)
White
(n=118)
YRI
(n=90)
CEU
(n=90)
YRI
(n=118)
CEU
(n=120)
YRI
(n=22)
Europe
(n=150)
rs61760183 Exon 3 170G>A/R57Q – 0.004 – – – – – –
rs2306283 Exon 5 388A>G/N130D 0.63 0.36 0.81 0.39 0.08 0.38 0.91 0.41
rs11045818 Exon 5 411G>A/S137S – 0.12 0.03 0.14 0.01 0.16 0 0.16
rs11045819 Exon 5 463C>A/P155T 0.25 0.12 0.06 0.15 0.07 0.16 0.02 0.17
rs4149056 Exon 6 521T>C/V174A – 0.21 0.01 0.16 – 0.16 0.05 0.18
rs4149057 Exon 6 571T>C/L191L 0.88 0.44 0.15 0.67 0.19 0.63 0.14 0.61
rs2291076 Exon 6 597C>T/F199F 0.50 0.39 0.03 0.47 0.03 0.47 0.66 0.42
rs113495867 Exon 9 974insGTa – 0.004 – – – – – –
rs61760243 Exon 9 1034C>T/T345M – 0.004 – – – – – –
rs34671512 Exon 15 1929A>C/L643F 0.13 0.03 0.07 0.06 0.05 0.07 0.05 0.05
The minor allele frequencies in cases are compared with respective populations reported in HAPMAP, 1000 genome, and Pasanen et al. [16] publication.
SNP, single nucleotide polymorphism.
aA two base pair insertion in exon 9 results in a frameshift (FS) that encodes for a truncated 334 amino acid OATP1B1 transporter.
bHAPMAP notations are YRI (Yoruba in Ibadan, Nigeria) and CEU (Utah resident with Northern and Western European ancestry from the CEPH collection).
cPasanen et al. [16] is the source of this data. See publication for description of European population.
Table 2 Common SLCO1B1 haplotypes based on nonsynonymous SNPs in rhabdomyolysis cases
SNPs All cases 1000 genome Pasanen et al. [16]
Haplotype 388A>G 463C>A 521T>C 1929A>C
White
(n=118)
Black
(n=4)
CEU
(n=85)
YRI
(n=88)
Europe
(n=151)
North Africa
(n=29)
Sub-Saharan
(n=105)
*1a A C T A 0.56 0.38 0.58 0.16 0.56 0.24 0.21
*1b G – – – 0.07 0.25 0.04 0.7 0.26 0.48 0.77
*5 – – C – 0.07 – 0.01 0 0.02 0.02 –
*15 G – C – 0.14 – 0.13 0.01 0.16 0.16 0.02
*14 G A – – 0.11 0.25 0.2 0.05 – – –
*35 G – – C 0.03 0.13 0.03 0.06 – – –
The haplotype frequencies in cases are compared with Pasanen et al. [16] publication reporting and 1000 genome.
*1a is the reference haplotype.
SNP, single nucleotide polymorphism.
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reference sequence was on average greater than 13-fold
higher than that by cells with the empty vector
(0.2±0.01 vs. 0.01±0.006 pmol/mg of protein/min;
P<0.001), indicating a high capacity for OATP1B1-
specific transport. The transporter activity for the N130D
variant did not differ from the reference, whereas all of
the remaining variants showed a significant decrease in
uptake compared with reference (P<0.001). ES transport
by FS, *14, and R57Q was reduced 100, 97, and 82%,
respectively, compared with transport by the reference
OATP1B1 (P<0.001). A significant loss of function was
also noted for the *15 haplotype and the V174A, T345M,
and P155T variants [66, 55, 57, and 31% decrease (P<
0.001), respectively].
Cerivastatin uptake transport by SLCO1B1 variants and
haplotypes
Uptake transport of cerivastatin by HEK293/FRT cells
expressing OATP1B1 reference sequence was on average
2.5-fold higher than the empty vector cells (0.07±0.01
vs. 0.02±0.01 pmol/mg of protein/min; P<0.001), in-
dicating OATP1B1-specific transport. With the exception
of the T345M variant, in general, the effect of SLCO1B1
variants on cerivastatin transport was similar to the effect
on ES transport (Fig. 2). Transport of cerivastatin by the
FS, *14, and *15 transporters was barely detectable.
Significant reductions in cerivastatin transport were also
found for the R57Q, P155T, and V174A variants [82, 28,
and 68% decrease (P<0.001), respectively]. The T345M
variant demonstrated a substrate-dependent effect with
significant reduction in ES transport, whereas cerivastatin
transport remained unchanged.
Inhibitory effects of various drugs on OATP1B1-
mediated uptake of cerivastatin and ES
To determine whether concomitant medication use might
decrease OATP1B1-mediated uptake of cerivastatin, 15
drugs that were commonly used among the rhabdomyolysis
cases were screened for in-vitro inhibition of OATP1B1
function. The inhibitory effects of these compounds on
the uptake of [3H]-ES and [3H]-CER by HEK293/FRT
stably transfected with reference SLCO1B1 are shown in
Fig. 1
2−
ΔΔ
C
t
40 000
Re
fer
en
ce
 (
∗ 1a
)
Em
pt
y v
ec
to
r
R5
7Q
N1
30
D 
(∗ 1
b)
P1
55
T (
∗ 4)
V1
74
A 
(∗ 5
)
∗ 14 ∗ 15
T3
45
M FS
30 000
20 000
10 000
0
RT-qPCR analysis of mRNA expression of SLCO1B1 in stably
transfected HEK293/FRT cells. The mean±SD of 2DDCt for empty
vector and variants is calculated and plotted representing the fold
change in SLCO1B1 gene expression in transfected cells and empty
vector normalized to internal control gene (GAPDH). FS, frameshift;
RT-qPCR, reverse-transcription quantitative PCR.
Fig. 2
1.5
(a)
1.0
∗
∗
∗
∗
∗ ∗
∗
∗
∗
∗
∗
∗
∗
0.5
N
or
m
al
iz
ed
 E
S
 u
pt
ak
e
N
or
m
al
iz
ed
 C
E
R
 u
pt
ak
e
0
1.5
1.0
0.5
0
Re
fer
en
ce
 (
∗ 1a
)
R5
7Q
N1
30
D 
(∗ 1
b)
P1
55
T (
∗ 4)
V1
74
A 
(∗ 5
)
∗ 14 ∗ 15
T3
45
M FS
Re
fer
en
ce
 (
∗ 1a
)
R5
7Q
N1
30
D 
(∗ 1
b)
P1
55
T (
∗ 4)
V1
74
A 
(∗ 5
)
∗ 14 ∗ 15
T3
45
M FS
(b)
Effect of SLCO1B1 variants on estrone-3-sulfate (ES) and cerivastatin (CER) uptake transport. Intracellular accumulation of 20 nmol/l [3H]-ES (a)
and 5 nmol/l [3H]-CER (b) was measured in HEK293/FRT cells stably expressing SLCO1B1 reference and variants. Transport was expressed as
pmol/min/mg of protein. Data are normalized relative to OATP1B1 reference and are shown as mean±SD of results from three separate experiments.
Significant transport differences relative to reference were detected by one-way analysis of variance followed by post-hoc multiple comparison
testing (*P<0.001). FS refers to two base frameshift insertions (974insGT). FS, frameshift.
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Figs 3 and 4, respectively. As clopidogrel is a prodrug, we
also selected three of its inactive metabolites, clopidogrel
acid, 2-oxo clopidogrel, and clopidogrel acyl glucuronide
for testing. Rifampin, a known inhibitor of OATP1B1, was
tested as a positive control. Of the 19 compounds tested
(15 drugs, three metabolites of clopidogrel and rifampin),
11 inhibited the uptake of cerivastatin and 12 inhibited
the uptake of ES (Table 3). Celecoxib, clopidogrel acid,
diltiazem, irbesartan, and lansoprazole did not inhibit
OATP1B1-mediated cerivastatin or ES uptake even at
concentrations as high as 100 mmol/l (data not shown).
Fluoxymesterone, limited by solubility, was tested at
concentrations up to 3 mmol/l and no inhibitory effects on
OATP1B1-mediated uptake of cerivastatin and ES were
Fig. 3
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[3H]-ES was measured in HEK293/FRT cells stably expressing SLCO1B1 reference in the presence and absence of (a) amlodipine, (b) clopidogrel,
(c) 2-oxo clopidogrel, (d) clopidogrel acyl glucuronide, (e) glyburide, (f) levothyroxine, (g) montelukast, (h) pioglitazone, (i) rifampin, (j) rofecoxib, (k)
rosiglitazone, and (l) verapamil. All values are expressed relative to OATP1B1 control (no inhibitor) and are shown as mean±SEM of a representative
experiment. If there is no visible vertical bar, SEM is contained within the limits of the point marking the mean.
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observed (data not shown). Amlodipine, clopidogrel,
and its two metabolites, 2-oxo clopidogrel and clopidogrel
acyl glucuronide, glyburide, levothyroxine, montelukast,
pioglitazone, rofecoxib, and rosiglitazone inhibited
OATP1B1-mediated uptake of cerivastatin and ES.
Verapamil did not inhibit cerivastatin uptake at concen-
trations of up to 100 mmol/l, whereas it decreased ES
uptake by 68% at the concentration of 100 mmol/l only
(Figs 3 and 4).
For the tested drugs, the R value calculated using
extrapolated IC50 was greater than 2 only for rifampin
Fig. 4
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Inhibitory effects of various pharmaceuticals on the OATP1B1-mediated uptake of cerivastatin (CER). The OATP1B1-mediated uptake of 5 nmol/l
[3H]-CER was measured in HEK293/FRT cells stably expressing SLCO1B1 reference in the presence and absence of (a) amlodipine, (b)
clopidogrel, (c) 2-oxo clopidogrel, (d) clopidogrel acyl glucuronide, (e) glyburide, (f) levothyroxine, (g) montelukast, (h) pioglitazone, (i) rifampin, (j)
rofecoxib, (k) rosiglitazone, and (l) verapamil. All values are expressed relative to OATP1B1 control (no inhibitor) and are shown as mean±SEM of a
representative experiment. If there is no visible vertical bar, SEM is contained within the limits of the point marking the mean.
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(our positive control), with both cerivastatin and ES as
substrates. Rifampin inhibition of cerivastatin and ES
uptake produced R values of 2.18 and 8.56, respectively
(Table 3). For all other drugs, despite in-vitro inhibition, the
R values did not achieve the threshold for potential clinical
significance of 2. However, the R values did achieve the
threshold of 1.25 for clopidogrel, 2-oxo clopidogrel, and
rofecoxib for cerivastatin (Table 3). The R value for 2-oxo
clopidogrel was 1.26 with ES as a substrate (Table 3).
Among all the drugs screened for interaction with
cerivastatin, rofecoxib had the highest R value of 1.7.
Discussion
The resequencing of SLCO1B1 in our unique population
of 122 individuals that experienced rhabdomyolysis while
on cerivastatin identified two rare and four common
(>1% minor allele frequency) nonsynonymous variants
and one rare FS polymorphism, which we have previously
reported [6]. Three of these variants, the FS polymorph-
ism as well as the common haplotype *14, significantly
reduced OATP1B1-mediated cerivastatin uptake. Our
findings confirm the well-established in-vivo and in-vitro
effect of the 521T>C allele in SLCO1B1*5 and
SLCO1B1*15 haplotypes that is associated with a
significant reduction in uptake of atorvastatin [23,24],
cerivastatin [6,23], rosuvastatin [24], pitavastatin [25],
simvastatin [5,26], and pravastatin [27–31]. We cannot
rule out the possibility that decreased transport function
is a result of decreased expression of OATP1B1 on the
cell membrane. Attempts to quantify OATP1B1 levels in
the stable cell lines were not successful.
In general, the effect of nonsynonymous variation
followed a similar pattern for cerivastatin and ES uptake,
with the T345M variant being the only exception. The
T345M variant leads to a reduced ES uptake (0.43±0.07
of reference) with no effect on cerivastatin uptake,
indicating a substrate-dependent effect on activity for
this variant. Interestingly, the SLCO1B1*15 haplotype
significantly reduced ES uptake, whereas the effect on
CER uptake was less dramatic, an observation similar to
that reported by Kameyama et al. [23].
As cerivastatin-induced rhabdomyolysis, and more gen-
erally statin-induced rhabdomyolysis, is associated with
elevated plasma concentration of statins and their active
metabolites [10], the reduction in uptake of statins by
OATP1B1 variants is expected to lead to higher
cerivastatin exposure and an increased risk of rhabdo-
myolysis. The V174A variant has been associated with an
increased risk of simvastatin-induced [5] myopathy and
cerivastatin-induced [6] rhabdomyolysis. Given that the
R57Q, P155T, and FS variants, as well as OATP1B1*15
and *14 haplotypes, were shown to have reduced uptake
transport in vitro, they might increase the plasma
concentration of cerivastatin and perhaps other statins,
so that individuals with these variants could be at
increased risk for rhabdomyolysis. However, this hypoth-
esis requires confirmation in a clinical study.
A consequence of carrying SLCO1B1 variants that cause a
reduction in hepatic uptake of cerivastatin is reduced
metabolism of cerivastatin. The importance of the
OATP1B1 transporter in cerivastatin metabolism is high-
lighted in a recent publication showing that OATP1B1
inhibition by siRNA led to a 20–30% reduction in total
uptake of cerivastatin into human hepatocytes, 50%
reduction in formation of M-1 cerivastatin metabolite,
and no change in M-23 formation [32]. Transporter–
enzyme interplay is now well recognized as an im-
portant factor influencing drug metabolism [33,34]. With
respect to cerivastatin, exposure to this statin in kidney
transplant patients receiving cyclosporine, a known
OATP1B1 and CYP3A4 inhibitor, was three- to five-fold
higher than healthy volunteers on cerivastatin alone [35].
Table 3 Inhibitor IC50 and R values for OATP1B1-mediated uptake of cerivastatin
Drug name Oral dose (mg) Cmax
a (ng/ml) fu Iin, max (mmol/l) CER IC50 (mmol/l) ES IC50 (mmol/l) R (CER) R (ES)
Amlodipine 10 18 0.07 1.67 35.5 39.6 1.00 1.00
Clopidogrel 75 2 0.02 14.54 3.95 >100 1.10 –
600 31.4 0.02 124.40 3.95 >100 1.63 –
2-Oxo clopidogrel 600 0.05 0.02 118.69 8.18 8.97 1.29 1.26
Clopidogrel acyl glucuronide 600 – – – 10.9 33.5 – –
Glyburide 5 105 0.002 0.89 0.26 1.40 1.01 1.00
Levothyroxine 0.6 591 0.01 0.79 0.88 2.04 1.01 1.00
Montelukast 10 542 0.01 2.06 2.04 1.40 1.01 1.01
Pioglitazone 30 1500 0.01 9.82 39.6 6.80 1.00 1.01
Rifampinb 600 10 000 0.11 60.76 5.65 0.88 2.18 8.56
Rofecoxib 25 320 0.13 6.32 1.17 5.65 1.70 1.15
Rosiglitazone 8 598 0.002 2.39 43.4 4.27 1.00 1.00
Verapamil 120 272 0.1 18.2 >100 75.7 NA 1.02
Pharmacokinetic parameters, extrapolated IC50 values for OATP1B1-mediated uptake of CER and ES and prediction of clinical significance of the drug–drug interaction
(R) are shown for drugs tested as OATP1B1 inhibitors.
CER, cerivastatin; ES, estrone sulfate.
aCmax source(s): amlodipine [17], celecoxib [17], clopidogrel [17–19], 2-oxo clopidogrel [19], glyburide [17], levothyroxine [20], montelukast [17], pioglitazone [17],
rifampin [21], rofecoxib [17], rosiglitazone [17], and verapamil [17,22].
bPositive control.
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Furthermore, OATP1B1 was recently shown to be the
rate limiting step in atorvastatin hepatic clearance at a
subtherapeutic microdose [36]. This suggests that in the
subset of cerivastatin-induced rhabdomyolysis cases
reported by Kaspera et al. [8] to have ‘normal’ or
overactive CYP2C8 function, reduced function of
OATP1B1 might be a significant risk factor for toxicity,
thus mitigating any protective effect from normal or
increased CYP2C8 activity. In fact, 67 of 118 white
rhabdomyolysis cases (57%) (data not shown) reported by
Kaspera et al. [8] to have no change or increase in
CYP2C8-mediated cerivastatin metabolism carry at least
one copy of a SLCO1B1 polymorphism that we have
identified in our in-vitro experiments to have reduced
cerivastatin uptake. However, in the absence of informa-
tion about a control group, the contribution of these
variants to the risk of clinical events remains uncertain.
Furthermore, the impact of these variants needs to be
validated in a clinical pharmacokinetic study.
We also explored potential drug–drug interactions result-
ing in decreased OATP-mediated drug transport. Our
in-vitro data identified clopidogrel, 2-oxo clopidogrel, and
clopidogrel acyl glucuronide as modest inhibitors of
OATP1B1. Although our epidemiological study identified
a clinically significant clopidogrel–cerivastatin interaction
further confirmed by in-vitro metabolism assays [7], the
clinical significance of our OATP1B1 cellular data
requires further investigation. The ITC [13] suggests
that R values greater than 2 should trigger clinical follow-
up studies, whereas the Food and Drug Administration –
Center for Drug Evaluation Research [15] recommenda-
tion sets the threshold at R values greater than 1.25. In
fact neither cutoff is validated and the choice of cutoff
value is controversial. Depending on the cutoff selected
for determining the potential clinical significance of our
in-vitro data either none or three (clopidogrel, 2-oxo
clopidogrel, and rofecoxib) of the drugs/metabolites
should be considered for clinical evaluations according
to these guidelines. The R values calculated for
clopidogrel (R=1.1 and 1.63 at clopidogrel doses of 75
and 600mg, respectively) and 2-oxo clopidogrel (R=1.29
at clopidogrel dose of 600mg) depending on the selected
cutoff may or may not reach the threshold for clinical
follow-up but are consistent with our epidemiological
findings. Given the potential for drug interaction and
high concomitant use of statins and clopidogrel an in-vivo
follow-up might be given further consideration.
It is important to note that for most compounds tested,
we are not able to obtain data for a full IC50 curve, because
the inhibition of OATP1B1 at the highest tested
concentration was not complete. In the case of clopido-
grel, the maximal OATP1B1 inhibition of cerivastatin
uptake was 52.7%. Although our data support clopidogrel
and its two tested metabolites as OATP1B1 inhibitors, the
curves are insufficient to determine a formal IC50 value.
Although clopidogrel has been the subject of much
attention recently because of drug–gene interactions with
CYP2C19 and its variants [37] as well as controversial
drug–drug interactions with omeprazole, [38] the current
data are the first to identify clopidogrel as an inhibitor of
OATP1B1. Although there is some evidence suggesting a
potential interaction of clopidogrel with statins that are
metabolized by CYP3A4 (e.g. atorvastatin, simvastatin),
this has received limited clinical attention [39,40].
To our knowledge, these data are the first to identify
amlodipine, rofecoxib, levothyroxine, and montelukast as
inhibitors of OATP1B1 transport. Verapamil [41], glybur-
ide [42], rosiglitazone [43], and pioglitazone [43] were
previously identified as inhibitors of OATPB1. With the
exception of rifampin, none of the inhibitors tested
achieved the ITC recommended R value of 2 for a
clinically significant drug interaction.
Conclusion
Although we recognize that a proper evaluation of the
potential genetic and environmental risk factors de-
scribed in this paper would require a control group of
cerivastatin users, the data in this study suggest that
certain genetic variations in SLCO1B1 and coadminis-
tered drugs found in our rhabdomyolysis cases can alter
cerivastatin transport and subsequent metabolism in vivo
such that they might increase the risk for adverse
reactions. Although cerivastatin is no longer in clinical
use, these findings may be translatable to related statins,
most of which carry a reduced but measurable risk of a
muscle toxicity, and other substrates of OATP1B1.
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